Yes, TGF-beta (transforming growth factor-beta) is a cytokine. More specifically, it heads one of the largest and most versatile cytokine families in the human body, with over 30 related proteins that regulate everything from immune function to wound healing to embryonic development. It is often described as the most pleiotropic cytokine family, meaning its effects span a wider range of tissues and biological processes than nearly any other signaling molecule.
What Makes TGF-Beta a Cytokine
Cytokines are small proteins that cells release to send signals to other cells. TGF-beta fits this definition precisely: it is secreted by many cell types, travels to neighboring or distant cells, binds to receptors on their surface, and triggers changes in gene activity. What sets TGF-beta apart from simpler cytokines is the sheer number of cell types it affects and the complexity of its responses, which can be opposite depending on the context.
The TGF-beta family divides into two major subfamilies based on structure and function. The first, the TGF-beta/Nodal subfamily, includes the three TGF-beta isoforms (TGF-beta 1, 2, and 3), Nodal, four activins, and several growth and differentiation factors. The second is the bone morphogenetic protein (BMP) subfamily, which includes eleven BMPs, four additional growth and differentiation factors, and anti-Müllerian hormone. In total, these proteins form one of the body’s most elaborate cell-to-cell communication networks.
The Three Isoforms and Where They Work
Mammals produce three versions of TGF-beta, and each has a distinct primary role. TGF-beta 1 is the workhorse of adult tissue maintenance. It is the most abundant isoform in adult organs, with especially high concentrations in the spleen and bone marrow (around 400 nanograms per gram of tissue), where it is produced largely by megakaryocytes, the cells that generate platelets. Immune tissues like the thymus and lymph nodes contain moderate levels of TGF-beta 1 and only trace amounts of the other two isoforms.
TGF-beta 2 and TGF-beta 3 are more active during embryonic development than in adult life. TGF-beta 2 is found at its highest levels in the lungs but remains far less abundant than TGF-beta 1 across all tissues. It also has a unique signaling requirement: it needs a co-receptor called betaglycan to connect with the main signaling receptors, something the other isoforms don’t require. TGF-beta 3 is highly localized within specialized regions of developing tissues, and in adults, the mammary gland is the only organ where it is expressed at significant levels. Knockout studies in mice illustrate how critical each isoform is: mice lacking TGF-beta 1 die from autoimmune-like inflammation, those without TGF-beta 2 die before birth from organ defects, and those missing TGF-beta 3 die immediately after birth because cleft palate prevents them from nursing.
How TGF-Beta Sends Its Signal
TGF-beta signals through a pathway that is elegant in its simplicity compared to many other cytokine cascades. When a TGF-beta molecule binds to its receptor on a cell’s surface, it brings together two types of receptor proteins, called type I and type II. The type II receptor activates the type I receptor by adding a phosphate group to it. The now-active type I receptor does the same thing to proteins inside the cell called Smads.
These activated Smad proteins then team up with a partner called Smad4, forming a complex that moves into the cell’s nucleus. Once there, the Smad complex works with other cofactors to turn specific genes on or off. This is how a single molecule landing on the outside of a cell can change what that cell produces, how it behaves, or whether it survives. TGF-beta also activates alternative signaling routes outside this main Smad pathway, which partly explains why its effects vary so dramatically from one cell type to another.
TGF-Beta’s Role in the Immune System
One of TGF-beta’s most important jobs is keeping the immune system in check. It does this primarily by driving the creation of regulatory T cells, a specialized class of immune cells that prevent the body from attacking its own tissues. TGF-beta converts ordinary helper T cells into regulatory T cells by initiating and maintaining the expression of a master control gene called Foxp3. This process also requires signals from the T cell receptor and a growth factor called IL-2, but TGF-beta is the key ingredient.
The regulatory T cells generated by TGF-beta suppress multiple arms of the immune response. They dampen the killing activity of cytotoxic T cells, reduce antibody production, and inhibit inflammatory responses from the innate immune system. In transplant research, TGF-beta-driven regulatory T cells have been shown to reduce inflammation against transplanted pancreatic islets and improve graft survival. This immunosuppressive power is a double-edged sword: it protects against autoimmunity but can also shield tumors from immune attack.
Wound Healing and Fibrosis
TGF-beta is one of the body’s primary wound-healing signals, but when that process goes into overdrive, it causes fibrosis, the excessive buildup of scar tissue in organs. The mechanism behind both involves a process called epithelial-mesenchymal transition, or EMT. During EMT, cells that normally sit in organized sheets (epithelial cells) transform into mobile, matrix-producing cells. TGF-beta is one of the most potent triggers of this transformation.
During EMT, cells ramp up production of structural proteins like fibronectin and alter the types of collagen and adhesion molecules they express. This is useful in wound repair, where mobile cells need to migrate into damaged areas and lay down new tissue. But in chronic disease, the same process deposits excessive connective tissue in organs like the lungs, liver, and kidneys. Making things worse, cells undergoing EMT produce molecules that activate even more latent TGF-beta stored in the surrounding tissue, creating a self-reinforcing cycle of fibrosis.
The Cancer Paradox
Perhaps the most striking feature of TGF-beta is that it plays opposite roles at different stages of cancer. In healthy tissue and early-stage tumors, TGF-beta acts as a tumor suppressor by stopping cell growth and promoting cell death. But as cancers progress, they find ways to dodge these growth-inhibiting effects through genetic and epigenetic changes. Mutations in the tumor suppressor gene p53 appear to be one mechanism that flips this switch.
Once the switch occurs, cancer cells don’t just ignore TGF-beta. They actively exploit it. The same cytokine that once restrained them now promotes their ability to migrate, invade surrounding tissue, stimulate blood vessel growth, and suppress the immune cells that would otherwise attack the tumor. This dual nature has made TGF-beta a particularly challenging therapeutic target, because blocking it could simultaneously slow metastasis and remove a brake on early tumor growth.
TGF-Beta as a Therapeutic Target
The involvement of TGF-beta in cancer and fibrotic diseases has made it a major focus of drug development. As of mid-2023, 124 agents designed to block TGF-beta signaling had been identified worldwide, with two receiving regulatory approval and 73 still in clinical trials. Six of those agents are in late-stage (phase III) trials, and 33 are in phase II.
These drugs target TGF-beta at multiple points in its signaling chain. Some block production of the protein itself at the genetic level. Others are antibodies that intercept TGF-beta molecules before they reach their receptors. A third approach uses small molecule inhibitors that block the type I receptor, preventing it from activating Smads inside the cell. These various strategies are being tested across a range of cancers, including pancreatic, breast, lung, prostate, and colorectal cancers, as well as fibrotic conditions like idiopathic pulmonary fibrosis and myelofibrosis.
Elevated TGF-beta 1 levels in the blood are also being studied as a potential biomarker. In bile duct cancer, serum TGF-beta 1 levels can distinguish patients from healthy individuals with roughly 71% sensitivity and 69% specificity, and higher levels correlate with metastasis, more advanced disease stages, and shorter survival times. While not yet a standard diagnostic test, this line of research reflects how central TGF-beta is to disease progression.